Year: 2013
Type: review
Source: Biological Psychiatry
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: U.S. Department of Veterans Affairs, Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, State of Connecticut Department of Mental Health and Addiction Services, Yale University, Gilead Sciences, Teva Pharmaceutical Industries, F. Hoffmann-La Roche, Sunovion, Georgia Clinical and Translational Science Alliance, Eisai, Shire, Astellas Pharma, Merz Pharmaceuticals, H. Lundbeck A/S, Astellas Pharma Global Development, Pfizer Pharmaceuticals, National Center for PTSD, U.S. Department of Veterans Affairs, National Institute on Alcohol Abuse and Alcoholism, National Institute of Mental Health, National Center for Research Resources, Janssen Pharmaceuticals
Awards: G1041632141, 1/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression, Effects of Stress and Glutamatergic Agents on Glutamate Cycling and Behavior, G4264513427, Role of GABA Interneurons in the Rapid Antidepressant Actions of NMDA Receptor Blockade, PSYCHOTOGENIC DRUG ACTION ON CHEMICALLY DEFINED NEURONS, Studies of Amino Acid Neurotransmitter Contributions to Depression, G7420383591, Yale University Clinical and Translational Science Award Program, Psychotogenic Drug Action on Chemically Defined Neurons, Center for the Translational Neuroscience of Alcoholism
OpenAlex ID: W2018114814